How do you treat patients with newly diagnosed metastatic MiT Family Translocation Renal Cell Carcinoma?

The AREN1721 clinical trial is accepting patients of all ages with unresectable or metastatic TFE/translocation renal cell carcinoma (RCC). The tumors must have either TFE3 expression by immunohistochemical staining or evidence of a TFE3 or TFEB translocation. The three arm trial compares nivolumab,...

Data regarding systemic therapy for patients with metastatic translocation (TFE3 translocation) RCC is limited to observational studies. For first line therapy, I will suggest clinical trial or VEGF-directed therapy such as sunitinib (Malouf et al., PMID 20154303, Choueiri et al., PMID 20665500) or ...